

Demetra acquires majority assets of Next Science, LTD, a leading provider of proven solutions for addressing microbial burden, reinforcing the leadership of Demetra as a company of choice for Infection management.

September 15, 2025 – Demetra, an innovative and independent international medical company leader providing bone cements, spacers and biomaterials for orthopedic applications and orthopedic infection control, announces a **strategic asset purchase from Next Science**, LTD a medical technology, Australian-based company with a research and development centre in Jacksonville, Florida, USA, established in 2012, the company's primary focus on the development and commercialization of its proprietary technologies designed to reduce the impact of infections in human health.

For over 40 years, Demetra has been a trusted partner to healthcare professionals worldwide in orthopedics, improving the lives of nearly 3 million people through advanced solutions in infection control, prosthesis fixation, and orthobiologics, and renowned globally thanks to the success of Tecres, Osartis and OsteoRemedies technology solutions. The addition of these technologies, backed by compelling scientific research and clinical validation, will allow Demetra to provide a market leading portfolio of infection management solutions. Osartis, a Demetra company, will take ownership of these assets globally and work with the teams over the coming months to ensure a smooth transition.

Harry Hall IV, Managing Director and CEO of Next Science, stated: *"This sale ensures the innovations developed by our Next Science team will reach more patients than ever before. With Demetra's international presence and ability to scale, the technologies we created are well positioned to advance infection management and make a lasting difference for patients and clinicians worldwide."*

Positioning for growth in the US and beyond

"By acquiring Next Science's cutting-edge technologies, we take another decisive step in expanding the Demetra PJI portfolio and beyond. This move strengthens our long-standing collaboration with healthcare professionals and reaffirms our purpose-driven approach, bringing transformative solutions to improve lives across the globe". commented Michele Perrino, CEO of Demetra.

Chris Hughes, President & CEO of OsteoRemedies further commented *"Next Science provides OsteoRemedies with additional data driven, yet simple solutions to offer our surgeons and patients. As we continue to build on our market leading position for infection management, I am excited about how well this matches our Vision."*

About Demetra S.p.A.

Demetra S.p.A. is an independent global healthcare group specialized in the development of PJI treatment solutions and minimally invasive surgical solutions. With a presence in over 100 countries and a growing portfolio of patented technologies, Demetra is committed to advancing patient care by investing in people, research, and sustainable innovation.

DEMETRA HOLDING S.P.A.

Corso Monforte 16, 20122 Milano, Italia - T. +39 045 9217311 - F. +39 045 9217330 - info@demetraholding.it - www.demetraholding.com
P.IVA 09446320963 - R.E.A. MI-2090614 - Cap. Soc. € 760.526 i.v.

